Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Satellos Bioscience Inc (MSCL.VN)
Satellos Bioscience Inc (MSCL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63,163
  • Shares Outstanding, K 112,792
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,322 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.36
Trade MSCL.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings $-0.03 on N/A
  • Latest Earnings Date 04/04/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.450 +24.44%
on 01/15/24
0.610 -8.20%
on 01/18/24
+0.100 (+21.74%)
since 01/12/24
3-Month
0.350 +60.00%
on 11/16/23
0.610 -8.20%
on 01/18/24
+0.210 (+60.00%)
since 11/14/23
52-Week
0.290 +93.10%
on 11/14/23
0.850 -34.12%
on 04/25/23
+0.150 (+36.59%)
since 02/14/23

Most Recent Stories

More News
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
Satellos Expands Leadership Team with New CFO Appointment

Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.Current CFO, Warren Whitehead, CPA,...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
August Jobs Figure Roll out Next Week in U.S.

Monday U.S. Featured Earnings Heico Corporation (NYSE:HEI) (Q3) Reported EPS for 74 cents, ...

AFYA : 20.91 (+0.60%)
NAT : 4.14 (-0.97%)
HPQ : 28.34 (-1.32%)
LULU : 468.10 (+0.85%)
DDL : 1.1500 (-10.16%)
EGT.VN : 0.020 (unch)
HEI.VN : 0.180 (unch)
MSCL.VN : 0.560 (+1.82%)
LA.VN : 11.490 (+8.40%)
TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite

/CNW/ - Frank Gleeson, Chief Executive Officer, Satellos Bioscine (TSXV: MSCL) ("Satellos" or the "Company") shares his Company's story in an interview with...

MSCL.VN : 0.560 (+1.82%)
TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite

/PRNewswire/ - Frank Gleeson, Chief Executive Officer, Satellos Bioscine (TSXV: MSCL) ("Satellos" or the "Company") shares his Company's story in an interview...

MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with DuchenneToronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Appointment of Chief Medical Officer

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine...

MSCLF : 0.5127 (+3.79%)
MSCL.VN : 0.560 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.593
2nd Resistance Point 0.587
1st Resistance Point 0.573
Last Price 0.560
1st Support Level 0.553
2nd Support Level 0.547
3rd Support Level 0.533

See More

52-Week High 0.850
Fibonacci 61.8% 0.636
Fibonacci 50% 0.570
Last Price 0.560
Fibonacci 38.2% 0.504
52-Week Low 0.290

See More

Business Summary

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar